009420 — Hanall Biopharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapHigh Flyer

Annual income statement for Hanall Biopharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	88,602	101,594	109,995	134,910	138,944
Cost of Revenue
Gross Profit	50,651	60,333	61,971	75,172	73,306
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	82,712	91,495	108,490	132,728	138,659
Operating Profit	5,891	10,100	1,506	2,182	284
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	19,225	8,702	1,929	3,203	-183
Provision for Income Taxes
Net Income After Taxes	19,764	8,896	251	3,509	-1,805
Net Income Before Extraordinary Items
Net Income	19,764	8,896	251	3,509	-1,805
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	19,764	8,896	251	3,509	-1,805
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	387	187	4.73	69.7	-30.5
Dividends per Share